BA3011 for advanced solid tumors

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

1 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study involves taking a study drug called BA3011. The overall goal of this study is to see if BA3011 is a possible treatment for patients with sarcoma.
 

Eligibility & Criteria

IRB #:
21-019142
Official Title:
BA3011-001: A Phase 1/2 Dose Escalation And Dose Expansion Study Of BA3011 Alone And In Combination With Nivolumab In Adult And Adolescent Patients 12 Years And Older With Advanced Solid Tumors
Study Phase:
Phase I
Phase II
Eligible Age Range:
12 - 30 Years
Gender:
All
Study Categories:

Visit Criteria

The purpose of this study is to evaluate the safety and tolerability in the study drug, BA3011. This study will enroll patients 12 years of age and older that have been diagnosed with advanced sarcoma that hasn't responded to other treatments. The overall goal of this study is to see if BA3011 is a possible treatment for patients with sarcoma. Subjects will receive BA3011 either alone or in combination with Nivolumab. Both are administered via IV infusion. Study visits include the following assessments: blood draws, electrocardiograms (ECGs), and tissue collection (if a tumor biopsy is performed as part of regular clinical care). Reimbursement for travel may be provided.

Leader
Theodore W. Laetsch

Theodore Laetsch, MD